УРИНАРНАЯ МИКРОБИОТА И ЕЕ РОЛЬ ПРИ ОНКОУРОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЯХ
- Авторы:Хаккулов Эркин Бекмирзаевич, Алимов Жалолиддин Усмонхон угли, Гафуров Бахтиёр Қахрамонович, Мирзарахимов Хусан Абдугани угли, Раҳматуллаев Акмалжон Ортиғали ўғли
- Дата публикации:November 17, 2026
- Тип:Статья
- DOI: 10.64156/mju.9972 Скопировано
- Том / № Выпуска:Том 1 №6 (2026)
Аннотация
Аннотация. Короткий курс антибактериальной терапии способен значительно изменить состав уринарной и кишечной микробиоты. Наиболее чувствительными оказываются представители родов Lactobacillus, Corynebacterium, Streptococcus и Bifidobacterium, выполняющие защитные функции. Развитие представлений о микробиоте стало возможным благодаря совершенствованию лабораторных технологий. Современные методы исследования можно условно разделить на культуральные, молекулярно-генетические и мультиомные. Одним из наиболее перспективных направлений является полногеномное секвенирование микробных сообществ. Уринарный дисбиоз рассматривается как потенциальный биомаркер неблагоприятного течения заболевания и возможная терапевтическая мишень для персонализированной сопроводительной терапии. Таким образом, современные данные свидетельствуют о тесной взаимосвязи между микробиотой, иммунной системой и результатами противоопухолевого лечения.
Ключевые слова: Онкоурология, уринарной микробиоты, уринарный дисбиоз, андроген-депривационная терапия.
Annotatsiya. Qisqa muddatli antibiotik davolash siydik va ichak mikrobiotasi tarkibini sezilarli darajada o’zgartirishi mumkin. Eng sezgir bo’lganlari Lactobacillus, Corynebacterium, Streptococcus va Bifidobacterium genuslariga mansub, himoya funksiyalarini bajaradigan turlardir. Mikrobiotani tushunishimizdagi yutuqlar laboratoriya usullari takomillashuvi tufayli amalga oshirildi. Zamonaviy tadqiqot usullari madaniy, molekulyar-genetik va ko’p-omli yondashuvlarga keng tasniflanadi. Eng istiqbolli sohalardan biri mikrobiyal jamoalarning butun genomini sekvenlashdir. Siydik disbiyosi kasallik prognozining yomon bo’lishi mumkin bo’lgan biomarkeri va shaxsiylashtirilgan qo’shimcha terapiya uchun mumkin bo’lgan terapevtik maqsad sifatida qaraladi. Shunday qilib, hozirgi dalillar mikrobiota, immunitet tizimi va saratonga qarshi davolash natijalari o’rtasidagi yaqin bog’liqlikni ko’rsatadi.
Kalit so’zlar: Urologik onkologiya, siydik mikrobiotasi, siydik disbiyosi, androgen yetishmovchiligi terapiyasi.
Abstract. A short course of antibiotic treatment can significantly alter the composition of the urinary and gut microbiota. The most susceptible are members of the genera Lactobacillus, Corynebacterium, Streptococcus and Bifidobacterium, which perform protective functions. Advances in our understanding of the microbiota have been made possible by improvements in laboratory techniques. Modern research methods can be broadly categorised into culture-based, molecular-genetic and multi-omic approaches. One of the most promising areas of research is whole-genome sequencing of microbial communities. Urinary dysbiosis is regarded as a potential biomarker of poor disease prognosis and a possible therapeutic target for personalised adjuvant therapy. Thus, current evidence points to a close relationship between the microbiota, the immune system and the outcomes of anticancer treatment.
Keywords: Urological oncology, urinary microbiota, urinary dysbiosis, androgen deprivation therapy.
References
- Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer. 2019; 135:196-204. doi: 10.1016/j.lungcan.2019.07.010
- Hendriks LE, Kerr KM, Menis J, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Non–oncogene-addicted metastatic non–small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358-376. doi: 10.1016/j.annonc.2022.12.013
- Izumi K, Iwamoto H, Yaegashi H, et al. Gemcitabine plus cisplatin split versus gemcitabine plus carboplatin for advanced urothelial cancer with cisplatin-unfit renal function. In Vivo. 2019;33(1):167-172. doi:10.21873/invivo.11454
- Jimenez-Labaig P, Mirallas O, Martin-Quesada AI, et al. Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis. J Immunother Cancer. 2025;13(11): e013072. doi:10.1136/jitc-2025-013072
- Kim YR, Lee JL, You D, et al. Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma. Cancer Chemother Pharmacol. 2015;76(1):141-153. doi:10.1007/s00280-015-2774-z
- Kua VF, Ismail F, Chee Ee Phua V, Aslan NM. Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2013;14(2):1121-1126. doi:10.7314/APJCP. 20–13.14.2.1121
- Mansoor M, Shakil F, Jalal U, et al. Comparison of the efficacy of cisplatin/paclitaxel versus carboplatin/paclitaxel in improving survival and quality of life in the advanced ovarian cancer patient population: a systematic review and meta-analysis of randomized control trials. Cureus. 2023;15(12): e51011. doi:10.7759/cureus.51011
- Mourey L, Flechon A, Tosi D, et al. Vefora, GETUG-AFU V06 study: randomized multicenter phase II/III trial of fractionated cisplatin (CI)/gemcitabine (G) or carboplatin (CA)/g in patients (pts) with advanced urothelial cancer (UC) with impaired renal function (IRF)—results of a planned interim analysis. J Clin Oncol. 2020;38(6) (suppl):461. doi: 10.1200/JCO.2020.38.6_suppl.461
- Muggia FM, Bonetti A, Hoeschele JD, Rozencweig M, Howell SB. Platinum antitumor complexes: 50 years since Barnett Rosenberg’s discovery. J Clin Oncol. 2015;33(35):4219-4226. doi:10.1200/JCO.2015.60.7481
- Nag S, Ray Coquard I, Gupta S, et al. Pan-Asia adapted ESMO clinical practice guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer. ESMO Open. 2025;10(6):105125. doi: 10.1016/j.esmoop.2025.105125
- NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2. National Comprehensive Cancer Network; 2026. Accessed July 3, 2026. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417
- Oaknin A, Gladieff L, Martínez-García J, et al; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024;403(10421):31-43. doi:10.1016/S0140-6736(23)02405-4
- Omland LH, Lindberg H, Carus A, et al. Real-world treatment patterns and overall survival in locally advanced and metastatic urothelial tract cancer patients treated with chemotherapy in Denmark in the preimmunotherapy era: a nationwide, population-based study. Eur Urol Open Sci. 2020; 24:1-8.
- PADCEVTM plus Keytruda® significantly improves survival for patients with muscle-invasive bladder cancer regardless of cisplatin eligibility. Pfizer Inc. December 17, 2025. Accessed February 17, 2026. https://www.pfizer.com/news/press-release/press-release-detail/padcevtm-plus-keytrudar-significantly-improves-survival
- Patrikidou A, Cazzaniga W, Berney D, et al. European Association of Urology guidelines on testicular cancer: 2023 update. Eur Urol. 2023;84(3):289-301. doi: 10.1016/j.eururo.2023.04.010
- Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125-1135. doi:10.1056/NEJMoa2035807
- Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer: an analysis of Veterans Health Administration data. J Thorac Oncol. 2014;9(5):702-709. doi:10.1097/JTO.0000000000000146